GENERAL
Sun Pharmaceutical Agrees To MFN Pricing For US Medicaid Programmes
Sun Pharmaceutical Industries has joined several pharmaceutical companies in announcing agreements with the US government aimed at prioritising access to affordable medicines for millions of American patients. Under its agreement, Sun Pharma will extend Most Favoured Nation (MFN) pricing to state Medicaid programmes. The company has also committed to MFN pricing for future innovative medicine […]
CW Bureau
·
Sep 1, 2026
GENERAL
Sun Pharma Receives Big Legal Boost As US Court Upholds Lipitor Ruling
Sun Pharmaceutical Industries Ltd has secured a significant legal victory in long-running antitrust litigation in the US related to its 2008 patent litigation settlement with Pfizer concerning generic Lipitor (Atorvastatin). The United States Court of Appeals for the Third Circuit has affirmed the order of the US District Court granting summary judgment in its entirety […]
CW Bureau
·
Aug 17, 2026
GENERAL
Sun Pharma Receives Organon Shareholders Nod For $11.75-Bn Buy
Leading global pharmaceutical company Sun Pharmaceutical Industries Ltd has received shareholder approval from Organon & Co. for its proposed acquisition. The approval marks a key milestone towards completion of the transaction. Following the deal, Organon will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA Inc., an indirect wholly owned subsidiary of Sun Pharma. […]
CW Bureau
·
Jul 24, 2026
GENERAL
Sun Pharma To Acquire Innovcare For ₹271 Cr To Bolster Product Portfolio
Sun Pharmaceutical Industries has signed an agreement to acquire 100% of Mumbai-based Innovcare Lifesciences Pvt Ltd for ₹271 crore in cash, strengthening its product portfolio in the pharmaceuticals, nutraceuticals and cosmeceuticals segments. The pharmaceutical company informed stock exchanges on Saturday that the acquisition will be completed on or before July 31, 2026. The transaction is […]
CW Bureau
·
Jun 20, 2026
GENERAL
Sun Pharmaceuticals To Acquire Organon In $11.75-Bn All-Cash Deal
Sun Pharmaceutical Industries Ltd, leading specialty generics company, will acquire Organon at $14 per share in an all-cash transaction, valuing the company at an enterprise value of $11.75 billion, funded through internal accruals and borrowings. The transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the […]
CW Bureau
·
Apr 27, 2026
